High-dose NGN-401 has been well-tolerated, and low-dose NGN-401 continues to show a favorable safety profileInterim safety data presented at the International Rett Syndrome Foundation (IRSF) ASCEND SummitNeurogene Inc.
CrowdStrike detects advanced adversary attack in real-world, closed-book simulation in just four minutes, six to 11 times faster than competitive vendors; scores highest in detection coverage at 98%CrowdStrike
Palantir shares closed Monday up 6.15% after Argus Research analyst Joseph Bonner initiated coverage on the stock with a Buy rating and announced a price target of $29, highlighting momentum around the company's commercial business.
AstraZeneca announced that the CAPItello-290 Phase 3 trial for Truqap (capivasertib) combined with paclitaxel in advanced or metastatic triple-negative breast cancer did not meet primary endpoints for overall survival.
Trump Media & Technology Group shares are down in premarket trading despite a recent surge, as the company addresses short selling concerns and plans expansion into streaming and media acquisitions.